Literature DB >> 18498023

Cardiac sympathetic hypo-innervation in familial dysautonomia.

David S Goldstein1, Basil Eldadah, Yehonatan Sharabi, Felicia B Axelrod.   

Abstract

OBJECTIVE: Familial dysautonomia (FD) involves incomplete development of the sympathetic nervous system. Whether such loss extends to sympathetic innervation of the heart has been unknown. This study used 6-[(18)F]fluorodopamine neuroimaging to assess cardiac sympathetic innervation and function in FD.
METHODS: Six adult FD patients underwent thoracic PET scanning for 30 minutes after i.v. 6-[(18)F]fluorodopamine injection, as did healthy volunteers without (N = 21) or with (N = 10) pre-treatment by desipramine, which interferes with neuronal uptake and thereby simulates effects of noradrenergic denervation. Effective rate constants for uptake and loss were calculated using a single compartment pharmacokinetic model.
RESULTS: FD patients had decreased uptake and accelerated loss of 6-[(18)F]fluorodopamine-derived radioactivity in the interventricular myocardial septum (P = 0.009, P = 0.05) and ventricular free wall (P = 0.007, P < 0.001), compared to untreated controls. Desipramine-treated subjects had decreased uptake but normal loss of 6-[(18)F]fluorodopamine-derived radioactivity.
CONCLUSIONS: FD involves cardiac noradrenergic hypo-innervation. Since accelerated loss of 6-[(18)F]fluorodopamine-derived radioactivity cannot be explained by decreased neuronal uptake alone, FD may also involve augmented NE loss from extant terminals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18498023      PMCID: PMC5245918          DOI: 10.1007/s10286-008-0464-1

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  24 in total

1.  Electrocardiographic repolarization abnormalities in familial dysautonomia: an indicator of cardiac autonomic dysfunction.

Authors:  J S Glickstein; F B Axelrod; D Friedman
Journal:  Clin Auton Res       Date:  1999-04       Impact factor: 4.435

Review 2.  A world without pain or tears.

Authors:  Felicia B Axelrod
Journal:  Clin Auton Res       Date:  2006-04       Impact factor: 4.435

3.  Serum dopamine-beta-hydroxylase in familial dysautonomia.

Authors:  L S Freedman; R P Ebstein; M Goldstein; F B Axelrod; J Dancis
Journal:  J Lab Clin Med       Date:  1975-06

4.  Quantitative studies of sympathetic ganglia and spinal cord intermedio-lateral gray columns in familial dysautonomia.

Authors:  J Pearson; B A Pytel
Journal:  J Neurol Sci       Date:  1978-11       Impact factor: 3.181

Review 5.  Pacemakers in patients with familial dysautonomia--a review of experience with 20 patients.

Authors:  Gabrielle Gold-von Simson; Monika Rutkowski; Dena Berlin; Felicia B Axelrod
Journal:  Clin Auton Res       Date:  2005-02       Impact factor: 4.435

6.  Cardiac sympathetic denervation in Parkinson disease.

Authors:  D S Goldstein; C Holmes; S T Li; S Bruce; L V Metman; R O Cannon
Journal:  Ann Intern Med       Date:  2000-09-05       Impact factor: 25.391

7.  Survival in familial dysautonomia: Impact of early intervention.

Authors:  Felicia B Axelrod; Judith D Goldberg; Xiang Y Ye; Channa Maayan
Journal:  J Pediatr       Date:  2002-10       Impact factor: 4.406

8.  Deficient sympathetic nervous response in familial dysautonomia.

Authors:  M G Ziegler; C R Lake; I J Kopin
Journal:  N Engl J Med       Date:  1976-03-18       Impact factor: 91.245

9.  6-[18F]fluorodopamine positron emission tomographic scanning in the assessment of cardiac sympathoneural function--studies in normal humans.

Authors:  D S Goldstein; C Holmes; J E Stuhlmuller; J W Lenders; I J Kopin
Journal:  Clin Auton Res       Date:  1997-02       Impact factor: 4.435

10.  Renal disease in familial dysautonomia.

Authors:  J Pearson; G Gallo; M Gluck; F Axelrod
Journal:  Kidney Int       Date:  1980-01       Impact factor: 10.612

View more
  15 in total

1.  Afferent baroreflex failure in familial dysautonomia.

Authors:  Lucy Norcliffe-Kaufmann; Felicia Axelrod; Horacio Kaufmann
Journal:  Neurology       Date:  2010-11-23       Impact factor: 9.910

2.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

Review 3.  Hereditary Sensory and Autonomic Neuropathies: Adding More to the Classification.

Authors:  Coreen Schwartzlow; Mohamed Kazamel
Journal:  Curr Neurol Neurosci Rep       Date:  2019-06-20       Impact factor: 5.081

4.  Catecholamines 101.

Authors:  David S Goldstein
Journal:  Clin Auton Res       Date:  2010-07-11       Impact factor: 4.435

5.  BGP-15 prevents the death of neurons in a mouse model of familial dysautonomia.

Authors:  Sarah B Ohlen; Magdalena L Russell; Michael J Brownstein; Frances Lefcort
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

Review 6.  Sympathetic neuroimaging.

Authors:  David S Goldstein
Journal:  Handb Clin Neurol       Date:  2013

7.  IKAP expression levels modulate disease severity in a mouse model of familial dysautonomia.

Authors:  Paula Dietrich; Shanta Alli; Revathi Shanmugasundaram; Ioannis Dragatsis
Journal:  Hum Mol Genet       Date:  2012-08-24       Impact factor: 6.150

Review 8.  Assessment of cardiac autonomic neuronal function using PET imaging.

Authors:  James T Thackeray; Frank M Bengel
Journal:  J Nucl Cardiol       Date:  2013-02       Impact factor: 5.952

Review 9.  Roles of catechol neurochemistry in autonomic function testing.

Authors:  David S Goldstein; William P Cheshire
Journal:  Clin Auton Res       Date:  2018-04-28       Impact factor: 4.435

10.  Nonuniform cardiac denervation observed by 11C-meta-hydroxyephedrine PET in 6-OHDA-treated monkeys.

Authors:  Valerie Joers; Kailie Seneczko; Nichole C Goecks; Timothy J Kamp; Timothy A Hacker; Kevin G Brunner; Jonathan W Engle; Todd E Barnhart; R Jerome Nickles; James E Holden; Marina E Emborg
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.